Biotech Adam Feuerstein STAT Plus: FDA places clinical hold on Verve Therapeutics gene-editing treatment
Biotech Ryan Cross — The Boston Globe STAT Plus: Muscular dystrophy patient who was first in line for a custom CRISPR therapy dies
Biotech Adam Feuerstein and Damian Garde STAT Plus: A turnaround for Editas Medicine, a CRISPR laggard, hinges on updates on key treatments
Biotech Megan Molteni STAT Plus: A new suite of RNA-sensing tools could help scientists target cancerous cells, and much more
Biotech Jason Mast STAT Plus: Biotech turns to new and strange viruses to overcome gene therapy’s limitations
The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein Listen: Biden’s Covid declaration, twilight of the SPAC, & genome editing 2.0
Biotech Allison DeAngelis STAT Plus: New CRISPR startup, drawing big-name backers, seeks to fix diseases caused by large DNA errors
Pharmalot Ed Silverman STAT Plus: Pharmalittle: CRISPR-based drug shows promise in preliminary study; FDA user fee program prompts fresh worries over conflicts
Biotech Megan Molteni STAT Plus: Intellia says CRISPR treatment safely corrects DNA of six patients with rare disease
The Readout LOUD Damian Garde and Adam Feuerstein Listen: CRISPR for the heart, biotech’s recovery, & what it means to be a ‘hot girl’
Biotech Jason Mast STAT Plus: Beyond a CRISPR treatment’s encouraging results, some scientists see a need for more data on risk
In the Lab Megan Molteni CRISPR debuted 10 years ago, in a paper hardly anyone noticed. Jennifer Doudna reflects on the DNA scissors’ first decade
Biotech Adam Feuerstein STAT Plus: Updated study results show a CRISPR treatment for blood diseases continues to benefit patients
Biotech Adam Feuerstein STAT Plus: A Caribou CAR-T treatment, backed by Nobel-winning science, shows blood-cancer remissions in first data reveal
First Opinion Walter G. Johnson and Diana M. Bowman It’s time for Congress to stop blocking mitochondrial replacement therapy
Biotech Megan Molteni STAT Plus: In the wake of big patent decision, it’s business as usual for CRISPR therapy developers
Exclusive Megan Molteni STAT Plus: New details emerge about a U.S. scientist’s obscured role in the ‘CRISPR babies’ scandal
The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein Listen: Biden’s plans for Covid pills, the latest vaccine data, & fighting about CRISPR
Biotech Megan Molteni STAT Plus: UC Berkeley loses CRISPR patent case, invalidating patent rights it granted gene-editing companies developing human therapies
Biotech Adam Feuerstein STAT Plus: Intellia Therapeutics shows improved, sustained effect from in vivo CRISPR treatment
Biotech Megan Molteni STAT Plus: With new trial data coming, Intellia CEO talks up the future of in vivo gene editing
The Readout LOUD Damian Garde and Meg Tirrell STAT Plus: Jennifer Doudna and Marty Chavez on where CRISPR meets Wall Street
The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein Listen: Robert Califf’s FDA return, the future of CRISPR, & another vaccine delay
In the Lab Megan Molteni Drugs based on next-generation gene editing are moving toward the clinic faster than CRISPR 1.0